Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fast Track designation
Biotech
Kyverna accelerates into another FDA fast track
Just days after declaring plans to go public, Kyverna has nabbed FDA fast track designation for its lead asset to treat multiple sclerosis.
Max Bayer
Jan 19, 2024 10:26am
Chasing Pfizer, Regenxbio benefits from FDA boost in DMD
Apr 11, 2023 9:45am
Ayala and Advaxis fuse together to pool funds for lead programs
Oct 19, 2022 11:00am
FDA grants Silence's drug fast-track tag for a blood cancer
Sep 8, 2022 9:10am
Racing Bayer, Merck gets FDA fast-track tag for anticoagulant
Aug 23, 2022 8:40am
Vor's cancer cell therapy gets on FDA's fast track
Sep 10, 2021 6:07am